Division of Endocrinology, Department of Medicine, University Health Network-Toronto General Hospital, 200 Elizabeth Street, 12 EN-212, Toronto, Ontario, Canada M5G 2C4.
Support Care Cancer. 2012 Mar;20(3):641-5. doi: 10.1007/s00520-011-1302-x. Epub 2011 Nov 10.
We explored regret in thyroid cancer patients, relating to the decision to accept or reject adjuvant radioactive iodine treatment.
We studied patients with a recent diagnosis of early stage papillary thyroid carcinoma, in whom treatment decisions on adjuvant radioactive iodine had been finalized. Participants completed a Decision Regret Scale questionnaire. We asked the participants to identify who made the final decision about radioactive iodine treatment. We explored the relationship between decision regret and a) degree of patient involvement in decision-making and b) receipt of radioactive iodine treatment.
We included 44 individuals, more than half of whom received adjuvant radioactive iodine treatment (26/44). Decision regret was generally low (mean 22.1, standard deviation [SD] 13.0). Participants reported that the final treatment decision was made by the following: patient and doctor (52.3%, 23/44), completely the patient (27.3%, 12/44), or completely the physician (20.5%, 9/44). Decision regret significantly differed according to who made the final decision: the patient (mean 19.0, SD 11.3), patient and doctor (mean 19.5, SD 7.4), and the doctor (mean 32.9, SD 20.37) (F = 4.569; degrees of freedom = 2, 41; p = 0.016). There was no significant difference in decision regret between patients who received radioactive iodine and those who did not (mean difference -2.5; 95% confidence interval -10.6, 5.6; p = 0.540).
Thyroid cancer patients who reported being involved in the final treatment decision on adjuvant radioactive iodine had less regret than those who did not.
我们探讨了甲状腺癌患者对接受或拒绝辅助放射性碘治疗这一决策的后悔程度。
我们研究了近期被诊断为早期乳头状甲状腺癌的患者，这些患者对辅助放射性碘的治疗决策已经确定。参与者完成了决策后悔量表问卷。我们请参与者确定谁做出了关于放射性碘治疗的最终决策。我们探讨了决策后悔与 a）患者参与决策的程度和 b）接受放射性碘治疗之间的关系。
我们纳入了 44 名个体，其中超过一半的人接受了辅助放射性碘治疗（26/44）。决策后悔程度普遍较低（平均值 22.1，标准差 [SD] 13.0）。参与者报告说，最终的治疗决策是由以下人员做出的：患者和医生（52.3%，23/44）、完全由患者（27.3%，12/44）或完全由医生（20.5%，9/44）。根据谁做出了最终决策，决策后悔有显著差异：患者（平均值 19.0，SD 11.3）、患者和医生（平均值 19.5，SD 7.4）以及医生（平均值 32.9，SD 20.37）（F=4.569；自由度=2,41；p=0.016）。接受放射性碘治疗和未接受放射性碘治疗的患者之间的决策后悔没有显著差异（平均差异-2.5；95%置信区间-10.6,5.6；p=0.540）。
报告参与辅助放射性碘治疗最终决策的甲状腺癌患者比未参与的患者后悔程度更低。
